Unbiased AI-powered news
1 stories related to this topic, newest first.
The TimesAstraZeneca announced an 8 percent increase in first-quarter revenue to $15.29 billion, exceeding analyst forecasts. The growth was driven by oncology and rare disease segments. The company reaffirmed its full-year outlook for revenue and earnings growth.